Packaging mockup
Growth Hormone & IGF · Long-acting GHRH analogue research
CJC-1295 (with DAC)
Scientific Product Dossier
Growth Hormone, Secretagogue & IGF Research
This center groups GH-axis hormones, releasing-hormone analogues, secretagogues and IGF-related research materials. Proteins, peptide analogues and small-molecule secretagogues require different identity and potency descriptions.
13 families found for “Growth Hormone & IGF”
Clear filterPackaging mockup
Growth Hormone & IGF · Long-acting GHRH analogue research
CJC-1295 (with DAC)
Scientific Product Dossier
Packaging mockup
Growth Hormone & IGF · Modified GRF(1-29) research
CJC-1295 (without DAC)
Scientific Product Dossier
Packaging mockup
Growth Hormone & IGF · Source-reviewed dossier
CJC-1295 (without DAC) + Ipamorelin Blend
Source-Reviewed Research Dossier
Packaging mockup
Growth Hormone & IGF · Source-reviewed dossier
GHRP-2 Acetate
Source-Reviewed Research Dossier
Packaging mockup
Growth Hormone & IGF · Source-reviewed dossier
GHRP-6 Acetate
Source-Reviewed Research Dossier
Packaging mockup
Growth Hormone & IGF · Source-reviewed dossier
Hexarelin Acetate
Source-Reviewed Research Dossier
Packaging mockup
Growth Hormone & IGF · Source-reviewed dossier
HGH (GA)
Source-Reviewed Research Dossier
Packaging mockup
Growth Hormone & IGF · Source-reviewed dossier
IGF-1 LR3
Source-Reviewed Research Dossier
Packaging mockup
Growth Hormone & IGF · Ghrelin-receptor agonist research
Ipamorelin
Scientific Product Dossier
Packaging mockup
Growth Hormone & IGF · Ghrelin-receptor agonist research
MK-677 (Ibutamoren)
Scientific Product Dossier
Packaging mockup
Growth Hormone & IGF · Source-reviewed dossier
PEG-MGF
Source-Reviewed Research Dossier
Packaging mockup
Growth Hormone & IGF · Source-reviewed dossier
Sermorelin
Source-Reviewed Research Dossier
Category knowledge center
How to evaluate this research category
This hub separates molecular identity, study design and lot documentation so related families can be explored without turning unlike evidence into a single claim.
- 13
- canonical families
- 31
- catalog variants
- 13
- reviewed dossiers
- 27
- linked source records
What this category includes
- Growth hormone and releasing-hormone research materials
- GHRP and ghrelin-receptor secretagogue families
- IGF and growth-factor related families
- Human endocrine, animal, mechanistic and analytical records
Identity and interpretation checks
- With-DAC and without-DAC CJC materials do not share the same pharmacokinetic evidence.
- A mass specification cannot be converted to IU without product-specific potency information.
- Endocrine biomarker elevation is not equivalent to a demonstrated clinical benefit.
Molecule class
Distinguish proteins, peptide analogues, fragments and non-peptide secretagogues before comparing evidence.
Potency units
Mass, international units and biological activity are not interchangeable without a defined conversion basis.
Hormone endpoint
GH pulse, integrated GH, IGF-1, body composition and functional outcomes answer different questions.
Continue the research
Comparisons and editorial analysis
Use fixed, reviewed comparison pages for defined questions and articles for deeper source context. Product dossiers remain the source for catalog identity and variants.
CJC-1295: DAC vs No DAC
An identity-first comparison explaining why the classic long half-life data for albumin-binding CJC-1295 cannot be assigned to products marketed as “CJC-1295 without DAC.”
Open comparison →Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured
An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.
Read analysis →Tesamorelin Research Material vs EGRIFTA WR: Why Formulation and Status Matter
A clear comparison between a tesamorelin research material and the FDA-approved EGRIFTA WR finished drug, focusing on formulation, documentation and evidence transfer.
Read analysis →Sermorelin Human Evidence: GH Response Tests and Historical Limits
Sermorelin is GHRH(1–29)-amide. Human research shows acute pituitary growth-hormone responses, while historical treatment data are limited and do not support modern anti-aging or performance…
Read analysis →Sermorelin Identity Guide: GHRH(1–29)-Amide and LC-MS
Sermorelin is an amidated 29-residue peptide corresponding to the active N-terminal region of human GHRH. The C-terminal amide is identity-defining.
Read analysis →PEG-MGF Evidence Gap: Native MGF, PEGDMA and a Common Mix-Up
Direct evidence for a defined covalently PEGylated MGF product is sparse. Several frequently cited papers instead placed native MGF peptide inside PEGDMA hydrogel devices—a…
Read analysis →PEG-MGF Quality Guide: PEG Size, Attachment and Characterization
“PEG-MGF” is not a complete molecular identity. A defensible material record must define the peptide, PEG architecture, attachment chemistry, site distribution and unmodified-peptide fraction.
Read analysis →Category questions
Evidence and identity FAQ
These answers define how the category is organized. They do not replace the product specification, lot documents or the cited study record.
Why are GH and IGF families not compared by mass alone?
Their molecular size, biological activity and unit conventions differ; the specification must state the applicable measurement basis.
Does an increase in GH prove a functional outcome?
No. Hormone exposure, downstream biomarkers, body composition and function are distinct endpoints.
What is the main CJC-1295 identity issue?
The classic long-acting human evidence concerns the DAC form; a product called without DAC needs its own explicit sequence and evidence boundary.